Puma Biotechnology | PBYI - Gross Profit On Sales

Stock Price
6.62
Daily Change
0.01 0.12%
Monthly
5.38%
Yearly
137.20%
Q1 Forecast
5.65

Puma Biotechnology reported $20.32M in Gross Profit on Sales for its fiscal quarter ending in September of 2024.





Gross Profit On Sales Change Date
Agios Pharmaceuticals USD 11.2M 448K Sep/2025
Alnylam Pharmaceuticals USD 1.05B 418.14M Sep/2025
Amgen USD 6.48B 307M Sep/2025
Biogen USD 1.65B 34.6M Dec/2025
BioMarin Pharmaceutical USD 631.2M 39.27M Sep/2025
Daiichi Sankyo JPY 439.83B 95.05B Dec/2025
Esperion Therapeutics USD -29.52M 32.4M Sep/2024
Exelixis USD 572.18M 7M Dec/2025
Gilead Sciences USD 6.31B 106M Dec/2025
Glaxosmithkline GBP 8.75B 2.92B Sep/2025
Incyte USD 1.39B 118.68M Dec/2025
MacroGenics USD 61.25M 88.71M Sep/2025
Moderna USD 809M 791M Sep/2025
Novartis USD 10.82B 695M Sep/2025
Pfizer USD 3.54B 7.61B Sep/2025
PTC Therapeutics USD 187.69M 24.3M Sep/2025
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Regeneron Pharmaceuticals USD 3.3B 67M Dec/2025
Roche Holding CHF 22.09B 10.04B Dec/2025
Sangamo BioSciences -2.39M 1.09M Jun/2024
Sarepta Therapeutics USD 247.9M 209.96M Sep/2025
Takeda JPY 790.55B 262.97B Dec/2025
TG Therapeutics USD 133.62M 11.41M Sep/2025
Ultragenyx Pharmaceutical USD 131.94M 11.55M Sep/2025
Vanda Pharmaceuticals USD 50.6M 5.5M Dec/2024
Vertex Pharmaceuticals USD 2.66B 104.4M Sep/2025